AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

RecruitingNAAges 19 Years - anyAllMin-Seok Kim
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults age 19 and above ( no age limit for elderly ) * Patients with cardiogenic shock requiring intensive care monitoring in ICU * Patients eligible for oral medication administration * Patients who have provided research participation consent through a written informed consent form Exclusion Criteria: * Unwilling or unable to obtain informed consent by the participant or substitute decision maker * Patients with mechanical circulatory support at the time of screening * Patients with acute coronary syndrome * Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery * Known hypersensitivity to beta-blockers * Patients with a history of bronchospasm or asthma * Patients with bradycardia or second or third-degree atrioventricular block * Patients with sick sinus syndrome, including sinoatrial block * Patients with untreated pheochromocytoma * Patients currently undergoing de-sensitization therapy * Patients who are currently pregnant, postpartum period within 30 days or breast-feeding
๐Ÿ’Š

What it tests

  • Pulmonary artery catheter
๐Ÿ“

Where

1 site
Asan Medical Center
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy